FY2026 Earnings Forecast for PVLA Issued By HC Wainwright

Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report) – Analysts at HC Wainwright issued their FY2026 EPS estimates for shares of Palvella Therapeutics in a report released on Friday, November 6th. HC Wainwright analyst A. Maldonado expects that the company will earn ($6.40) per share for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($6.26) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q4 2026 earnings at ($1.94) EPS, Q1 2027 earnings at ($2.22) EPS, Q2 2027 earnings at ($2.83) EPS, Q3 2027 earnings at ($3.42) EPS, Q4 2027 earnings at ($3.10) EPS, FY2027 earnings at ($11.57) EPS, FY2028 earnings at ($9.87) EPS, FY2029 earnings at ($4.28) EPS and FY2030 earnings at $6.30 EPS.

Several other brokerages have also recently issued reports on PVLA. William Blair began coverage on shares of Palvella Therapeutics in a report on Friday, October 16th. They set an “outperform” rating for the company. Chardan Capital restated a “buy” rating and issued a $240.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, October 28th. Truist Financial set a $207.00 target price on Palvella Therapeutics in a report on Wednesday, August 5th. Canaccord Genuity Group upped their price objective on shares of Palvella Therapeutics from $232.00 to $243.00 and gave the company a “buy” rating in a report on Monday. Finally, Raymond James Financial set a $226.00 target price on Palvella Therapeutics in a research note on Friday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $213.85.

Check Out Our Latest Stock Analysis on PVLA

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $163.94 on Tuesday. The company’s 50-day simple moving average is $143.61 and its 200-day simple moving average is $129.30. Palvella Therapeutics has a fifty-two week low of $72.22 and a fifty-two week high of $179.95.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($1.70) EPS for the quarter, beating the consensus estimate of ($1.78) by $0.08.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. KBC Group NV purchased a new stake in shares of Palvella Therapeutics in the first quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Palvella Therapeutics during the second quarter worth about $35,000. Sterling Capital Management LLC grew its holdings in shares of Palvella Therapeutics by 907.7% during the third quarter. Sterling Capital Management LLC now owns 393 shares of the company’s stock worth $54,000 after buying an additional 354 shares during the last quarter. Archer Investment Corp purchased a new position in shares of Palvella Therapeutics during the second quarter worth about $69,000. Finally, Quantbot Technologies LP acquired a new position in Palvella Therapeutics in the 2nd quarter valued at about $71,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Christopher Kiritsy sold 313 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total value of $49,141.00. Following the completion of the sale, the director owned 250 shares in the company, valued at $39,250. This represents a 55.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director George Jenkins sold 13,352 shares of the company’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $151.96, for a total transaction of $2,028,969.92. Following the completion of the sale, the director owned 161,893 shares of the company’s stock, valued at approximately $24,601,260.28. This trade represents a 7.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 61,056 shares of company stock valued at $8,756,946 in the last ninety days. 17.20% of the stock is currently owned by company insiders.

Key Palvella Therapeutics News

These are some of the PVLA news items that stood out recently:

  • Positive Sentiment: Canaccord Genuity Group reportedly expects PVLA shares to rise, providing a favorable analyst view. The report details, including any price target, were not included in the article summary. Article: Palvella Therapeutics Stock Price Expected to Rise
  • Positive Sentiment: HC Wainwright maintained a “Strong-Buy” rating and projects Palvella could reach positive earnings by FY2030, forecasting $6.30 per share. This long-range outlook may offer optimism, though it is a forecast rather than a near-term catalyst. MarketBeat analyst estimates
  • Negative Sentiment: HC Wainwright’s forecasts anticipate continued losses through FY2029, including a projected $11.57-per-share loss in FY2027. Those expected losses may weigh on sentiment despite the firm’s positive rating and longer-term profitability forecast. MarketBeat analyst estimates

About Palvella Therapeutics

(Get Free Report)

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

Recommended Stories

Earnings History and Estimates for Palvella Therapeutics (NASDAQ:PVLA)

Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.